Close

Anti-esxA T cell receptor (YC05), pCDTCR1 (TCR-YC0370)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-esxA T cell receptor (TCR) is constructed for the engineering of T cell to target ESAT-6 protein EsxA (IHSLLDEGKQSLTKL) restricted by HLA class II. The T cells are genetically modified through transduction with a lentiviral vector expressing esxA-specific T cell receptor.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • esxA
  • Target Species
  • Mycobacterium tuberculosis
  • Epitope
  • IHSLLDEGKQSLTKL
  • Format
  • Non-Modified TCR
  • Allele
  • HLA class II
  • Targeting Diseases
  • M. tuberculosis infection
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • YC05
  • Host Species
  • Human

Target

  • Introduction
  • The ability of a single TCR to cross-react with different pMHC (sometimes called TCR degeneracy) is a common feature of T cell biology and is thought to be functionally important in mounting a rapid and effective response to diverse foreign Ags. TCR cross-reactivity is also important in T cell selection processes, as a TCR must interact with a self-peptide to survive and be exported to the periphery. Finally, TCR cross-reactivity is important in the process that leads to transplant rejection through the recognition of a foreign MHC known as the alloantigen.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-esxA T cell receptor (YC05), pCDTCR1 (TCR-YC0370). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.